CIBC Asset Management Inc grew its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 4.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,864 shares of the medical equipment provider’s stock after acquiring an additional 868 shares during the quarter. CIBC Asset Management Inc’s holdings in Zimmer Biomet were worth $2,397,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Bank of Nova Scotia Trust Co. acquired a new stake in shares of Zimmer Biomet in the 3rd quarter worth $112,000. FNY Managed Accounts LLC acquired a new stake in shares of Zimmer Biomet in the 3rd quarter worth $117,000. BB&T Investment Services Inc. acquired a new stake in shares of Zimmer Biomet in the 2nd quarter worth $144,000. Cerebellum GP LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth $133,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of Zimmer Biomet in the 3rd quarter worth $140,000. 86.18% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have issued reports on ZBH. Robert W. Baird reaffirmed a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, January 31st. Cantor Fitzgerald reissued a “buy” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Monday, February 5th. BMO Capital Markets reissued a “buy” rating and set a $144.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, January 30th. Stifel Nicolaus raised Zimmer Biomet from a “hold” rating to a “buy” rating and raised their price objective for the stock from $120.00 to $168.00 in a research report on Wednesday, January 31st. Finally, Leerink Swann raised their price objective on Zimmer Biomet from $142.00 to $146.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $141.67.
Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, meeting analysts’ consensus estimates of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The company had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same period last year, the business posted $2.14 EPS. Zimmer Biomet’s revenue for the quarter was up 3.0% on a year-over-year basis. equities analysts anticipate that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date of this dividend was Thursday, December 28th. Zimmer Biomet’s dividend payout ratio (DPR) is 10.64%.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2018/02/10/cibc-asset-management-inc-buys-868-shares-of-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.